269 related articles for article (PubMed ID: 36750531)
21. Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study.
Patriquin CJ; Bogdanovic A; Griffin M; Kelly RJ; Maciejewski JP; Mulherin B; Peffault de Latour R; Röth A; Selvaratnam V; Szer J; Al-Adhami M; Horneff R; Tan L; Yeh M; Panse J
Adv Ther; 2024 May; 41(5):2050-2069. PubMed ID: 38573482
[TBL] [Abstract][Full Text] [Related]
22. Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients.
Ishiyama K; Nakao S; Usuki K; Yonemura Y; Ikezoe T; Uchiyama M; Mori Y; Fukuda T; Okada M; Fujiwara SI; Noji H; Rottinghaus S; Aguzzi R; Yokosawa J; Nishimura JI; Kanakura Y; Okamoto S
Int J Hematol; 2020 Oct; 112(4):466-476. PubMed ID: 32869125
[TBL] [Abstract][Full Text] [Related]
23. Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies.
Kulasekararaj AG; Griffin M; Langemeijer S; Usuki K; Kulagin A; Ogawa M; Yu J; Mujeebuddin A; Nishimura JI; Lee JW; Peffault de Latour R;
Eur J Haematol; 2022 Sep; 109(3):205-214. PubMed ID: 35502600
[TBL] [Abstract][Full Text] [Related]
24. Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: Achievements and pitfalls.
Risitano AM; Peffault de Latour R; Marano L; Frieri C
Semin Immunol; 2022 Jan; 59():101618. PubMed ID: 35764467
[TBL] [Abstract][Full Text] [Related]
25. Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bresnahan R; Houten R; Greenhalgh J; Nevitt S; Mahon J; Beale S; Boland A; Bhattacharyya D; Dundar Y; McEntee J; Gandhi S; Fleeman N; Chaplin M
Pharmacoecon Open; 2023 Jul; 7(4):525-536. PubMed ID: 37195551
[TBL] [Abstract][Full Text] [Related]
26. C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab.
de Castro C; Grossi F; Weitz IC; Maciejewski J; Sharma V; Roman E; Brodsky RA; Tan L; Di Casoli C; El Mehdi D; Deschatelets P; Francois C
Am J Hematol; 2020 Nov; 95(11):1334-1343. PubMed ID: 33464651
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Ariceta G
Expert Rev Clin Pharmacol; 2023 May; 16(5):401-410. PubMed ID: 37128905
[TBL] [Abstract][Full Text] [Related]
28. Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations.
Bodó I; Amine I; Boban A; Bumbea H; Kulagin A; Lukina E; Piekarska A; Zupan IP; Sokol J; Windyga J; Cermak J
Adv Ther; 2023 Jun; 40(6):2752-2772. PubMed ID: 37072660
[TBL] [Abstract][Full Text] [Related]
29. Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
Lee JW; Kulasekararaj AG
Expert Opin Biol Ther; 2020 Mar; 20(3):227-237. PubMed ID: 32011183
[No Abstract] [Full Text] [Related]
30. Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria.
Brodsky RA; Peffault de Latour R; Rottinghaus ST; Röth A; Risitano AM; Weitz IC; Hillmen P; Maciejewski JP; Szer J; Lee JW; Kulasekararaj AG; Volles L; Damokosh AI; Ortiz S; Shafner L; Liu P; Hill A; Schrezenmeier H
Haematologica; 2021 Jan; 106(1):230-237. PubMed ID: 31949012
[TBL] [Abstract][Full Text] [Related]
31. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey.
Dingli D; Matos JE; Lehrhaupt K; Krishnan S; Yeh M; Fishman J; Sarda SP; Baver SB
Ann Hematol; 2022 Feb; 101(2):251-263. PubMed ID: 34973099
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria.
Chonat S; Kulagin A; Maschan A; Bartels M; Buechner J; Punzalan R; Richards M; Ogawa M; Hicks E; Yu J; Baruchel A; Kulasekararaj AG
Blood Adv; 2024 Jun; 8(11):2813-2824. PubMed ID: 38551806
[TBL] [Abstract][Full Text] [Related]
33. Cost-Utility Analysis Comparing Pegcetacoplan to Anti-C5 Monoclonal Antibodies in the Treatment of Paroxysmal Nocturnal Hemoglobinuria.
Di Matteo S; Freilone R; Bruno GM; Notaro R; Moumene S; Martone N; Teruzzi C; Ciccarone A; Colombo GL
Clinicoecon Outcomes Res; 2024; 16():225-232. PubMed ID: 38623087
[TBL] [Abstract][Full Text] [Related]
34. Breakthrough Hemolysis Associated With COVID-19 Vaccination and Active COVID-19 Infection in a Patient With Paroxysmal Nocturnal Hemoglobinuria Maintained on Pegcetacoplan: A Case Report.
Boshkos MC; Fives KR; Phrathep DD; Healey KD; Patel M
Cureus; 2023 Mar; 15(3):e36240. PubMed ID: 37065335
[TBL] [Abstract][Full Text] [Related]
35. Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.
Peipert JD; Kulasekararaj AG; Gaya A; Langemeijer SMC; Yount S; Gonzalez-Fernandez FA; Ojeda Gutierrez E; Martens C; Sparling A; Webster KA; Cella D; Tomazos I; Ogawa M; Piatek CI; Wells R; Sicre de Fontbrune F; Röth A; Mitchell L; Hill A; Kaiser K
PLoS One; 2020; 15(9):e0237497. PubMed ID: 32886668
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies.
Peffault de Latour R; Brodsky RA; Ortiz S; Risitano AM; Jang JH; Hillmen P; Kulagin AD; Kulasekararaj AG; Rottinghaus ST; Aguzzi R; Gao X; Wells RA; Szer J
Br J Haematol; 2020 Nov; 191(3):476-485. PubMed ID: 32449174
[TBL] [Abstract][Full Text] [Related]
37. Interim analysis of post-marketing surveillance of ravulizumab for paroxysmal nocturnal hemoglobinuria in Japan.
Usuki K; Ikezoe T; Ishiyama K; Kanda Y; Gotoh A; Hayashi H; Shimono A; Kitajima A; Obara N; Nishimura JI
Int J Hematol; 2023 Sep; 118(3):311-322. PubMed ID: 37477863
[TBL] [Abstract][Full Text] [Related]
38. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies.
Röth A; Rottinghaus ST; Hill A; Bachman ES; Kim JS; Schrezenmeier H; Terriou L; Urbano-Ispizua Á; Wells RA; Jang JH; Kulasekararaj AG; Szer J; Aguzzi R; Damokosh AI; Shafner L; Lee JW
Blood Adv; 2018 Sep; 2(17):2176-2185. PubMed ID: 30171081
[TBL] [Abstract][Full Text] [Related]
39. Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNH.
Griffin M; Kelly RJ; Panse J; de Castro C; Szer J; Horneff R; Tan L; Yeh M; Peffault de Latour R
Blood Adv; 2024 Apr; 8(7):1776-1786. PubMed ID: 38315872
[TBL] [Abstract][Full Text] [Related]
40. Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria.
Griffin M; Kelly R; Brindel I; Maafa L; Trikha R; Muus P; Munir T; Varghese AM; Mitchell L; Nagumantry S; Gandhi S; Pike A; Kulasekararaj AG; Peffault de Latour R
Am J Hematol; 2024 May; 99(5):816-823. PubMed ID: 38348608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]